An international task force has provided recommendations for the use of medicinal cannabis for chronic pain. The guidelines were presented during the PAINWeek meeting of the American Associations for the Study of Pain.
In the new recommendations, the task force described approaches to dosing and regimens of medical cannabis for the treatment of chronic pain. The group was formed by clinicians from the countries of North America, Europe, Africa, Brazil and Australia, writes the MedPage Today portal.
The task force recommended considering the use of medical cannabis in patients with neuropathic, inflammatory, nociplastic and mixed pain. According to experts, an important part of successful treatment: choosing a regimen for the individual patient, taking into account age and previous cannabis use. The working group participants noted that this therapy shows the best results in older patients.
It is proposed to begin treatment with small and increasing doses of cannabidiol (CBD) and, if the patient does not respond to treatment, switch to small doses of tetrahydrocannabinol (THC). Oral administration has been proposed as the preferred route of drug administration.
Experts did not recommend prescribing medical cannabis for pregnant and breastfeeding women, or people with mental illness. The working group participants did not agree on the maximum and minimum permissible ages for its use.
As the authors of the guidelines note, medical cannabis has previously been proposed for the treatment of chronic pain, but many doctors still do not prescribe it due to the lack of reliable guidance on dosing and use.